Dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments.
Giovanni Grandi, Rossella E Nappi, Angelo Cagnacci, Vincenzina Bruni, Vincenzo Bettoli, Alessandro Gambera, Filippo Favalli, Enrico Colli, Pedro-Antonio Regidor
{"title":"Dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments.","authors":"Giovanni Grandi, Rossella E Nappi, Angelo Cagnacci, Vincenzina Bruni, Vincenzo Bettoli, Alessandro Gambera, Filippo Favalli, Enrico Colli, Pedro-Antonio Regidor","doi":"10.1080/13625187.2026.2695185","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Combined oral contraceptives (COC)s, besides offering a reliable and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects.</p><p><strong>Methods: </strong>While contraceptive use is the primary indication for COC use, a variety of medical conditions have been added in the summary of product characteristics (SmPC) of these formulations.</p><p><strong>Results: </strong>Dienogest, a 17a-cyanomethyl-17ß-hydroxy-4,9-estradien-3-one progestin is used in different dosage regimes with different oestrogens and with different release forms in contraception and has, depending on the type of COC additional medical treatment indications.</p><p><strong>Conclusions: </strong>This narrative review will focus on the effects, apart from contraception, of these COCs on female target organs like the uterus and the skin and clinical entities as the polycystic ovarian syndrome (PCOS).</p>","PeriodicalId":520795,"journal":{"name":"The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception","volume":" ","pages":"1-13"},"PeriodicalIF":2.0000,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/13625187.2026.2695185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Combined oral contraceptives (COC)s, besides offering a reliable and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects.
Methods: While contraceptive use is the primary indication for COC use, a variety of medical conditions have been added in the summary of product characteristics (SmPC) of these formulations.
Results: Dienogest, a 17a-cyanomethyl-17ß-hydroxy-4,9-estradien-3-one progestin is used in different dosage regimes with different oestrogens and with different release forms in contraception and has, depending on the type of COC additional medical treatment indications.
Conclusions: This narrative review will focus on the effects, apart from contraception, of these COCs on female target organs like the uterus and the skin and clinical entities as the polycystic ovarian syndrome (PCOS).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
